TITLE

Research Capsules

PUB. DATE
February 2008
SOURCE
Pharmaceutical Representative;Feb2008, Vol. 38 Issue 2, p11
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article offers information related to various studies on drugs in the U.S. The angiogenesis inhibitor Avastin plus interferon might result in longer progression-free survival times for kidney cancer patients than interferon alone. The Precedex injection might provide sedation for intensive care unit patients on respirators when compared with the currently recommended drug. The oral immunomodulatory drug Revlimid and dexamethasone may increase survival in patients with multiple myeloma.
ACCESSION #
28816890

 

Related Articles

  • Alternative synthesis of lenalidomide. Balaev, A.; Okhmanovich, K.; Fedorov, V. // Pharmaceutical Chemistry Journal;Feb2013, Vol. 46 Issue 11, p676 

    A three-step alternative synthesis of lenalidomide was developed. The proposed route produced the desired product in 59.8% yield and 99.6% purity.

  • Effect of Drawing Blood Specimens Proximal to an In-Place but Discontinued Intravenous Solution: Can Blood Be Drawn Above the Site of a Shut-Off IV?  // JAMA: Journal of the American Medical Association;4/21/89, Vol. 261 Issue 15, p2186 

    Presents the abstract of the study 'Effect of Drawing Blood Specimens Proximal to an In-Place but Discontinued Intravenous Solution: Can Blood Be Drawn Above the Site of a Shut-Off IV,' by David C. Read and colleagues from the Pathology Laboratory, New England Deaconess Hospital. Medical history...

  • Lenalidomide-Induced Pure Red Cell Aplasia. Dolai, Tuphan Kanti; Dutta, Shyamali; Mandal, Prakas Kumar; Saha, Sandeep; Bhattacharyya, Maitreyee // Turkish Journal of Hematology;Mar2014, Vol. 31 Issue 1, p99 

    A letter to the editor is presented related to the pure red cell aplasia, bone marrow failure disorder, induced by Lenalidomide, published in the March 2014 issue of the journal.

  • New class of anti-angiogenic drugs under development. Correa, Mark; Hasson, Matt; Nale, Patricia // Ocular Surgery News;11/25/2011, Vol. 29 Issue 22, p14 

    The article reports on integrin peptide therapy as a potential newcomer to the armamentarium of therapeutics used to treat vascular eye disease according to data delivered by eye expert Hugo Quiroz-Mercado at the American Academy of Ophthalmology meeting in Orlando, Florida, in October 2011.

  • Clinical translation of angiogenesis inhibitors. Kerbel, Robert; Folkman, Judah // Nature Reviews Cancer;Oct2002, Vol. 2 Issue 10, p727 

    Angiogenesis inhibitors are a new class of drugs, for which the general rules involving conventional chemotherapy might not apply. The successful translation of angiogenesis inhibitors to clinical application depends partly on the transfer of expertise from scientists who are familiar with the...

  • Closing In on Cancer. Park, Alice // Time;5/21/2001, Vol. 157 Issue 20, p60 

    Focuses on developments in cancer research as of May 2001. Mention of a prediction made by scientist James Watson concerning the development of a cure for some cancers; Introduction of the drug Gleevec, which seems to be effective in treating two rare types of cancer; Discussion of the...

  • Closing In on Cancer. Park, Alice // Time International (South Pacific Edition); 

    Focuses on developments in cancer research as of May 2001. Mention of a prediction made by scientist James Watson concerning the development of a cure for some cancers; Introduction of the drug Gleevec, which seems to be effective in treating two rare types of cancer; Discussion of the...

  • Bevacizumab and dose-intense temozolomide in recurrent high-grade glioma. Verhoeff, J. J. C.; Lavini, C.; van Linde, M. E.; Stalpers, L. J. A.; Majoie, C. B. L. M.; Reijneveld, J. C.; van Furth, W. R.; Richel, D. J. // Annals of Oncology;Aug2010, Vol. 21 Issue 8, p1723 

    Background: Angiogenesis inhibition is a rational treatment strategy for high-grade glioma (HGG). Combined antiangiogenic therapy and chemotherapy could be beneficial, taking advantage of different mechanisms of antitumour activity of both therapies. We carried out a phase I–II clinical...

  • Angiogenesis inhibitors revised and revived at AACR. Novak, Kristine // Nature Medicine;May2002, Vol. 8 Issue 5, p427 

    Reports on the renewed efforts in the debate on angiogenesis inhibitors at the American Association for Cancer Research held from April 6 to 10, 2002 in San Francisco, California. Statistics on the number of anti-angiogenic agents in clinical trials; Studies indicating that the timing with...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics